Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company, announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nanobiotix (NASDAQ: NBTX), a late-clinical stage biotechnology company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will feature a fireside chat with company management on Wednesday, September 11, 2024, at 9:30 AM EDT / 3:30 PM CEST in New York, NY.
Presenters include Laurent Levy, co-founder and chairman of the executive board, and Bart Van Rhijn, chief financial officer. The fireside chat will be webcast live from the company's website, with a replay available after the event. Nanobiotix is known for pioneering physics-based approaches to expand treatment possibilities for cancer patients.
Details
News Market Reaction – NBTX
The recorded move for NBTX in the trading session of this news was +4.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
PARIS and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, announced today that Company management will participate in a fireside chat at the upcoming H.C. Wainwright 26th Annual Global Investment conference. Please see below for details of the event.
H.C. Wainwright 26th Annual Global Investment conference
Date: Wednesday, September 11, 2024
Time: 9:30 AM EDT / 3:30 PM CEST
Location: New York, NY
Presenters: Laurent Levy, co-founder of Nanobiotix and chairman of the executive board & Bart Van Rhijn, chief financial officer of Nanobiotix
Webcast link: Click here
The fireside chat will be webcast live from the events page of the Investors section of the Company’s website. Replay of the webcast will be available following the event.
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
FR – Ulysse Communication Pierre-Louis Germain + 33 (0) 6 64 79 97 51 plgermain@ulysse-communication.com | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
Attachment
- 2024-09-03 -- NBTX -- Presenting @ HCW&Co -- FINAL
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.